Rheumatoid arthritis and proteus

Rheumatoid Arthritis and Proteus

Volumn 9780857299505, Issue , 2012, Pages 1-233

  Ebringer, Alan ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930146242     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-85729-950-5     Document Type: Book

References (155)

1. Aho K, Koskenvuo M, Tuominen J, Kaprio J. Occurrence of rheumatoid arthritis in a nationwide series of twins. J Rheumatol. 1986;13: 899-902.
2. Aletaha D, Funovits J, Smolen JS. Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. Ann Rheum Dis. 2011;70:733-9.
3. Badley EM, Tennant A. Impact of disablement due to rheumatic disorders in a British population: estimates of severity and prevalence from the Calderdale Rheumatic Disablement Survey. Ann Rheum Dis. 1993;52:6-13.
4. Brennan FM, Maini RN, Feldmann M. TNF-α - A pivotal role in rheumatoid arthritis? Br J Rheumatol. 1992;31:293-8.
5. Ebringer A, Rashid T, Wilson C. Molecular mimicry as the basis of new theory of autoimmunity. In: Zouali M, editor. Frontiers in autoimmunity. Amsterdam/Washington, DC: IOS Press; 2003. p. 79-99.
6. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al. Estimates of prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum. 2008;58:15-25.
7. Klareskog L, Padyukov L, Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol. 2007;A 19:49-54.
8. Lajas C, Abasolo L, Belladel B, Hernadez-Garcia C, Carmona L, Vargas E, et al. Costs and predictors of costs in rheumatoid arthritis: A prevalence based study. Arthritis Rheum. 2003;49:64-70.
9. McIntosh E. The costs of rheumatoid arthritis. Br J Rheumatol. 1996;35:781-90.
10. Schiff B, Mizrachi Y, Orgad S, Yaron M, Gazit E. Association of HLA-Aw 31 and HLA-DR1 with adult rheumatoid arthritis. Ann Rheum Dis. 1982;41:403-4.
11. Silman AJ, MacGregor AJ, Thomson W, Holligan S, Carthy D, Farhan A, et al. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol. 1993;32:903-7.
12. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. New Engl J Med. 1978;298:869-71.
13. Stastny P, Ball EJ, Khan MA, Olsen NJ, Pincus T, Gao X. HLA-DR4 and other genetic markers in rheumatoid arthritis. Br J Rheumatol. 1988;27(Suppl II):132-8.
14. Svendsen AJ, Holm NV, Kyvik K, Petersen PH, Junker P. Relative importance of genetic effects in rheumatoid arthritis: historical cohort study of Danish nationwide twin population. Br Med J. 2002;324:264-6.
15. Yelin EK. The cost of rheumatoid arthritis; absolute, incremental and marginal estimates. J Rheumatol. 1996;23:47-51.
16. Ziff M, Cavender D, Haskard D. Pathogenetic factors in rheumatoid synovitis. Br J Rheumatol. 1988;27(Suppl II):153-6.
17. Aceves-Avila FJ, Medina F, Fraga A. The antiquity of rheumatoid arthritis: A reappraisal. J Rheumatol. 2001;28:751-7.
18. Aceves-Avila FJ, Delgadillo-Ruano MA, Ramos-Remus C, Gomez-Vargas A. The "Hospital Real de San Josef de Los Naturales" and the rheumatic conditions found in New Spain during the sixteenth century. Reumatismo. 2002;54:62-6.
19. Buchanan WW, Kean WE. Rheumatoid arthritis: beyond the lymphocyte. J Rheumatol. 2001;28:691-2.
20. Bywaters E. Historical aspects of the aetiology of rheumatoid arthritis. Br J Rheumatol. 1988;27 Suppl 2:110-5.
21. Caughey DE. The arthritis of Constantine IX. Ann Rheum Dis. 1974;33:77-80.
22. Dequeker J. Arthritis in Flemish paintings. Br Med J. 1977;1:1203-5.
23. Dequeker J. Siebrandus Sixtius: evidence of rheumatoid arthritis of the robust reaction type in a seventeenth century priest. Ann Rheum Dis. 1992;51:561-2.
24. Rashid T, Ebringer A. Rheumatoid arthritis is linked to Proteus - The evidence. Clin Rheumatol. 2007;26:1036-43.
25. Snorrason E. Landré-Beauvais and his "Goutte Asthénique Primitive." ACTA Med SCAND. 1952; 142, Suppl. 266:115-8.
26. Thould AK, Thould BT. Arthritis in Roman Britain. Br Med J. 1983; 287:1909-11.
27. Bennet PH, Wood PNH. Population studies of the rheumatic diseases. Amsterdam: Excerpta Medica; 1968. p. 456.
28. Chandler RW, Robinson H, Masi AT. Serological investigations for evidence of an infectious aetiology of rheumatoid arthritis. Ann Rheum Dis. 1971;30:274-8.
29. Cowling P, Ebringer R, Ebringer A. Association of inflammation with raised serum IgA in ankylosing spondylitis. Ann Rheum Dis. 1980;39:545-9.
30. Ebringer A, Ptaszynska T, Corbett M, Wilson C, Macafee Y, Avakian H, et al. Antibodies to Proteus in rheumatoid arthritis. Lancet. 1985;ii:305-7.
31. Marmion BP. A microbiologist's view of investigative rheumatology. In: Dumonde DC, editor. Infection and immunology in the rheumatic diseases. Oxford: Blackwell; 1976. p. 245-58.
32. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar RA. Revision of Diagnostic Criteria for Rheumatoid Arthritis. Bull Rheum Dis. 1958;9:175-6.
33. Ebringer A, Shipley M, editors. Pathogenesis of ankylosing spondylitis and rheumatoid arthritis. Br J Rheum. 1988;27(Suppl. II):1-178.
34. Hanly J, Hassan J, Whelan A, Feighery C, Bresnihan B. The effect of gold therapy on rheumatoid factor synthesis by synovial membrane. Br J Rheumatol. 1985;24:103.
35. Hanly JG, Hassan J, Moriarty M, Barry C, Molony J, Casey E, et al. Lymphoid irradiation in intractable rheumatoid arthritis. A double- blind randomized study comparing 750-rad treatment with 2, 000 rad treatment. Arthritis Rheum. 1986;29:16-25.
36. Hassan J, Hanly J, Whelan A, Feighery C, Bresnihan B. In-vitro production of immunoglobulins in patients with active rheumatoid arthritis and changes with gold therapy. Irish J Med Sci. 1984; 153:256.
37. O'Farrell C, Price R, Fernandes L. Immune sensitization to dietary antigens associated with IgA rheumatoid factor in rheumatoid arthritis. Br J Rheumatol. 1986;Abstract (Suppl. 2), Abs. 89.
38. Rogers P, Hassan J, Bresnihan B, Feighery C, Whelan A. Antibodies to Proteus in rheumatoid arthritis. Br J Rheumatol. 1988;27(Suppl II): 90-4.
39. Ropes MW, Bennett GA, Cobb S, Jacox R, Jessar R. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958;9:175-6.
40. Bjarnason I, Williams P, So A, Zanelli GD, Levi AJ, Gumpel JM, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984;2:1171-3.
41. Borriello SP, Hudson MJ, Hill MJ. Investigation of the gastrointestinal bacterial flora. Clin Gastroenterol. 1978;7:329-49.
42. Deighton CM, Gray J, Bint AJ, Walker DJ. Specificity of the Proteus antibody response in rheumatoid arthritis. Ann Rheum Dis. 1992;51:1206-7.
43. Drasar BS, Barrow PA. Intestinal microbiology. 3rd ed. Wokingham: Van Nostrand Reinhold; 1985.
44. Guenzel MN. Escherichia, Klebsiella, Enterobacter, Serratia, Citrobacter and Proteus. In: Baron S, editor. Medical microbiology. 2nd ed. Menlo Park: Addison Wesley; 1986. p. 495-506.
45. Hentges DJ. Human intestinal microflora in health and disease. Chapter 1. New York: Academic; 1983.
46. Khalafpour S, Ebringer A, Abuljadayel I, Corbett M. Antibodies to Klebsiella and Proteus microorganisms in ankylosing spondylitis and rheumatoid arthritis patients measured by ELISA. Br J Rheumatol. 1988;27 Suppl 2:86-9.
47. Subair H, Tiwana H, Fielder M, Binder A, Cunningham P, Ebringer A, et al. Elevation in anti-Proteus antibodies in patients with rheumatoid arthritis from Bermuda and England. J Rheumatol. 1995;22:1825-8.
48. Tishler M, Caspi D, Aimog Y, Segal R, Yaron M. Increased incidence of urinary tract infection in patients with rheumatoid arthritis and secondary Sjögren's syndrome. Ann Rheum Dis. 1992;51:604-6.
49. Fielder M, Youinou P, Cantagrel A, Wilson C, Ebringer A. Elevation of anti-Proteus antibody titres in rheumatoid arthritis patients from Brest and Toulouse measured by immunofluorescence: A coded study. Clin Exp Rheumatol. 1994;12(Suppl II):S104, Abst C125.
50. Fielder M, Tiwana H, Youinou P, Le Goff P, Deonarain R, Wilson C, et al. The specificity of the of anti-Proteus antibody response in tissue typed rheumatoid arthritis patients from Brest. Rheumatol Int. 1995;15:79-82.
51. Mancini G, Carbonara HO, Heremans JF. Immunological quantification of antigens by single radial immunodiffusion. Immunochemistry. 1965;2:235-53.
52. Blankenberg-Sprenkels SHD, Fielder M, Feltkamp TEW, Tiwana H, Wilson C, Ebringer A. Antibodies to Klebsiella pneumonia in Dutch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis. J Rheumatol. 1998; 25:743-7.
53. Linssen A, Dekker-Saeys AJ, Dandrieu MR, Christiaans BJ, Baarsma GS, Tjoa ST, et al. Possible ankylosing spondylitis in acute anterior uveitis. Br J Rheumatol. 1983;22 Suppl 2:137-43.
54. Schellekens GA, de Jong BA, van den Hoogen FH, van de Putte LB, van Venrooij WJ. Citrulline is an essential component of antigenic determinants recognized by rheumatoid arthritis specific autoantibodies. J Clin Invest. 1998;101:273-81.
55. Toivanen P, Koskimies S, Granfors K, Eerola E. Bacterial antibodies in HLA-B27 positive individuals. Arthritis Rheum. 1993;36: 1633-5.
56. Trull AK, Ebringer R, Panayi GS, Colthorpe D, James DCO, Ebringer A. IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Scand J Rheumatol. 1983;12:249-53.
57. Davis MJ, Dawes PT, Fowler PD, Sheeran TP, Shadforth MF, Ziade F, et al. Comparison and evaluation of disease activity index for use in patients with rheumatoid arthritis. Br J Rheumatol. 1990;29: 111-5.
58. Ito K, Iida T, Ichino K, Tsunezuka M, Hattori M, Namba T. Obovatol and obovatal, novel biphenyl ether lignans from the leaves of Magnoliaobovata Thunb. Chem Pharm Bull. 1982;30:791-7.
59. Kjeldsen-Kragh J, Haugen M, Borchgrevink C, Laerum E, Eek M, Mowinkel P, et al. Controlled trial of fasting and one year vegetarian diet in rheumatoid arthritis. Lancet. 1991;338:889-902.
60. Kjeldsen-Kragh J, Rashid T, Dybwad A, Sioud M, Haugen M, Forre O, et al. Decrease in anti-Proteus mirabilis but not anti- Escherichia coli antibody levels in rheumatoid arthritis patients treated with fasting and a one year vegetarian diet. Ann Rheum Dis. 1995;54:221-4.
61. Midvedt T, Johansson G, Carlstedt-Duke B, Midvedt A-C, Norin KE, Gustafsson JA. The effect of a shift from a mixed to a lactovegetarian diet on some intestinal microflora associated characteristics. Microb Ecol Health Dis. 1990;3:33-8.
62. Peltonen R, Ling W-H, Hänninen O, Eerola E. An uncooked vegan diet shifts the profile of human fecal microflora: computerised analysis of direct stool sample gas-liquid chromatography profiles of bacterial cellular fatty acids. Appl Environ Microbiol. 1992;58:3660-6.
63. Peltonen R, Kjeldsen-Kragh J, Haugen M, Tuominen J, Toivanen P, Forre O, et al. Changes in fecal flora in rheumatoid arthritis patients during fasting and one year vegetarian diet. Br J Rheumatol. 1994;33:638-43.
64. Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
65. Cecil R, Nicholls E, Stansby W. Characteristics of Streptococci isolated from patients with rheumatic fever and chronic infectious arthritis. Am J Pathol. 1930;6:619-25.
66. Darlington G, Ramsey N, Mansfield J. Placebo controlled, blind study of dietary manipulation therapy in rheumatoid arthritis. Lancet. 1986;1:236-8.
67. Deighton CM, Gray J, Bint AJ, Walker DJ. Specificity of the Proteus antibody response in rheumatoid arthritis. Ann Rheum Dis. 1992;51:1206-7.
68. Ganapathi M, Rzewnicki D, Samols D, Jiang S, Kushner I. Effect of combination of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in HEP 3B cells. J Immunol. 1991;147:1261-5.
69. Rashid T, Darlington G, Kjeldsen-Kragh FO, Collado A, Ebringer A. Proteus IgG antibodies and C-reactive protein in English, Norwegian and Spanish patients with rheumatoid arthritis. Clin Rheumatol. 1999;18:190-5.
70. Silman A. Epidemiology and the rheumatic diseases. In: Maddison P, Isenberg D, Woo P, editors. Oxford textbook of rheumatology. Oxford: Oxford University Press; 1993. p. 499-513.
71. Aoki S, Yoshikawa K, Yokoyama T, Nonogaki T, Wasaki S, Mitsui T, et al. Role of enteric bacteria in the pathogenesis of rheumatoid arthritis: evidence for antibodies to enterobacterial common antigens in rheumatoid sera and synovial fluids. Ann Rheum Dis. 1996;55:363-9.
72. Newkirk MM, Goldbach-Mansky R, Senior BW, Klippel J, Schumacher HR, El-Gabalawy HS. Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)- positive rheumatoid arthritis. Rheumatology. 2005;44:1433-41.
73. Tani Y, Tiwana H, Hukuda S, Nishioka J, Fielder M, Wilson C, et al. Antibodies to Klebsiella, Proteus and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis. J Rheumatol. 1997;24:109-14.
74. Trull AK, Ebringer R, Panayi GS, Colthorpe D, James DCO, Ebringer A. IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis. Scand J Rheumatol. 1983;12:249-53.
75. Ebringer A, Wilson C, Ahmadi K, Corbett M, Rashid T, Shipley M. Rheumatoid arthritis as a reactive arthritis to Proteus Infection: prospects for therapy. In: Machtey I, editor. Progress in rheumatology, vol. 5. Petach-Tiqva: Rheumatology Service, Hasharon Hospital; 1993. p. 77-83.
76. Fairley KF, Grounds AD, Carson NE, Laird EC, Gutch RC, McCallum PHG, et al. Site of infection in acute urinary tract infection in general practice. Lancet. 1971;2:615-8.
77. McDonagh J, Gray J, Sykes H, Walker DJ, Bint AS, Deighton CM. Anti-Proteus antibodies and Proteus organisms in rheumatoid arthritis: A clinical study. Br J Rheumatol. 1994;33:32-5.
78. Ropes MW, Bennet GA, Cobb S, Jacox R, Jessar RA. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958;9:175-6.
79. Senior BW, Anderson GA, Morley KD, Kerr MA. Evidence that patients with rheumatoid arthritis have asymptomatic 'non-significant' Proteus mirabilis bacteriuria more frequently than healthy controls. J Hyg. 1999;38:99-106.
80. Wilson C, Thakore A, Isenberg D, Ebringer A. Correlation between anti-Proteus antibodies and isolation rates of Proteus mirabilis in rheumatoid arthritis. Rheumatol Int. 1997;16:187-9.
81. Chou PY, Fasman G. Prediction of the secondary structure of proteins from the amino acid sequence. Adv Enzymol. 1978;47: 145-7.
82. Ebringer A, Cunningham P, Ahmadi K, Wrigglesworth J, Hosseini R, Wilson C. Sequence similarity between HLA-DR1 and DR4 subtypes associated with rheumatoid arthritis and Proteus/Serratia haemolysins. Ann Rheum Dis. 1992;51:1245-6.
83. Garnier J, Osguthorpe DJ, Robson BI. Analysis of the accuracy and implication of simple methods for predicting the secondary structure of globular proteins. J Mol Biol. 1978;120:97-120.
84. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis: An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30:1205-13.
85. Hopp TP, Woods KR. Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci USA. 1981;78: 3824-8.
86. Maeda H, Juji T, Mitsui H, Sonozaki H, Okitsu H. HLA-DR4 and rheumatoid arthritis in Japanese people. Ann Rheum Dis. 1981;40:299-302.
87. Schiff B, Mizrachi Y, Orgad S, Yaron M, Gazit E. Association of HLA-Aw31 and HLA-DR1 with adult rheumatoid arthritis. Ann Rheum Dis. 1982;41:403-4.
88. Stastny P. Association of the B-cell alloantigen DRW4 with rheumatoid arthritis. N Engl J Med. 1978;298:869-71.
89. Uphoff TS, Welch RA. Nucleotide sequencing of the Proteus mirabilis calcium independent haemolysin genes (hpm A and hpm B) reveals sequence similarity with the Serratia marcescens haemolysin genes (shl A and shl B). J Bacteriol. 1990;170:3177-88.
90. Watanabe Y, Tokunaga K, Matsuki K, Takeuchi F, Matsuta K, Maeda A, et al. Putative amino acid sequence of HLA DRβ chain contributing to rheumatoid arthritis susceptibility. J Exp Med. 1989;169:2263-8.
91. Jones BD, Mobley HLT. Proteus mirabilis urease: nucleotide sequence determination and comparison with jack bean urease. J Bacteriol. 1989;171:6414-22.
92. Kimura T, Cheah KSE, Chan SDH, Lui VC, Mattei MG, van der Rest M, et al. The human β2 collagen (COLIIA2) chain molecular cloning of cDNA and genomic DNA reveals characteristics of a fibrillar collagen with differences in genomic organisation. J Biol Chem. 1989;264:13910-6.
93. Nepom GT, Byers P, Seyfried CR. HLA genes associated with rheumatoid arthritis. Identification of susceptibility genes using oligonucleotide probes. Arthritis Rheum. 1989;33:15-21.
94. Schnaitman CA. Outer membrane proteins of Escherichia Coli 0 III. J Bacteriol. 1974;118:442-53.
95. Takeuchi F, Kosuge E, Matsuta K, Nakano K, Tokunaga K, Juji T, et al. Antibody to a specific HLA-DR β1 sequence in Japanese patients with rheumatoid arthritis. Arthritis Rheum. 1990;33:1867-8.
96. Wilson C, Ebringer A, Ahmadi K, Wrigglesworth J, Tiwana H, Fielder M, et al. Shared amino acid sequences between major histocompatibility complex class II glycoproteins, type XI collagen and Proteus mirabilis in rheumatoid arthritis. Ann Rheum Dis. 1995; 54:216-20.
97. Albani S, Keystone EC, Nelson L. Positive selection in autoimmunity: Abnormal immune responses to a bacterial dnaJ antigenic determinant in patients with early rheumatoid arthritis. Nat Med. 1995;1:448-52.
98. Kloppenburg M, Breedveld FC, Terwiel J, Mallee C, Dijkmans RAC. Minocycline in active rheumatoid arthritis: A double blind, placebo controlled trial. Arthritis Rheum. 1994;37:629-36.
99. Langewitz P, Bank I, Zemer D, Book M. Treatment of resistant rheumatoid arthritis with minocycline: An open study. J Rheumatol. 1992;19:1502-4.
100. Tiwana H, Wilson C, Cunningham P, Binder A, Ebringer A. Antibodies to four gram-negative bacteria in Rheumatoid Arthritis which share sequences with the Rheumatoid Arthritis susceptibility motif. Oxford University Press, Br J Rheumatol. 1996;35:592-594.
101. Carty SM, Snowden M, Silman AJ. Should infection still be considered as the most likely triggering factor for rheumatoid arthritis ? J Rheumatol. 2003;30:425-9.
102. Nakai Y, Wakisaka A, Aizawa M, Itakura K, Nakai H, Ohashi A. HLA and rheumatoid arthritis in Japanese. Arthritis Rheum. 1981;24:722-5.
103. Rashid T, Leirisalo-Repo M, Tani Y, Hukuda S, Kobayashi S, Wilson C, et al. Antibacterial and antipeptide antibodies in Japanese and Finnish patients with rheumatoid arthritis. Clin Rheumatol. 2004;23:134-41.
104. Wallin J, Hillert J, Olerup O, Carlsson B, Strom H. Association of rheumatoid arthritis with a dominant DR1/Dw4, Dw14 sequence motif, but not with a T cell receptor β chain gene alleles or haplotypes. Arthritis Rheum. 1991;34:1416-24.
105. Barber LD, Bal V, Lamb JR, O'Hehir J, Yendle J, Hancock RJT, et al. Contribution of T-cell receptor contacting and peptide binding residues of the class II molecules of HLA-DR4.Dw10 to serologic and antigen specific T-cell recognition. Hum Immunol. 1991;32:110-8.
106. Green N, Alexander H, Olson A, Alexander S, Shinnick TM, Sutcliffe JG, et al. Immunogenic structure of the influenza virus haemagglutinin. Cell. 1982;28:477-87.
107. Hammer J, Gallazzi F, Bono E, Karr RW, Guenot J, Valsasnini P, et al. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J Exp Med. 1995;181: 1847-55.
108. Kaiser E, Bossinger CD, Colescott RL, Olsen DB. Colour test for terminal proline residues in solid phase synthesis of peptides. Ann Chem Acta. 1980;118:149-51.
109. Tiwana H, Wilson C, Alvarez A, Abuknesha R, Bansal S, Ebringer A. Cross-reactivity between the rheumatoid arthritis associated motif EQKRAA and structurally related sequences found in Proteus mirabilis. Infect Immun. 1999;67:2769-75.
110. Wilson C, Tiwana H, Ebringer A. Molecular mimicry between HLA-DR alleles associated with rheumatoid arthritis and Proteus mirabilis as the aetiological basis for autoimmunity. Microbes Infect. 2000;2:1489-96.
111. Boissier MC, Chiochia G, Ronzière MC, Herbage D, Fournier C. Arthritogenicity of minor collagens (types IX and XI) in mice. Arthritis Rheum. 1990;33:1-9.
112. Cunningham MW, Antone SM, Gulizia JM, McManus BM, Fischetti VA, Gaunt CJ. Cytotoxic and viral neutralizing antibodies crossreact with streptococcal M protein, enteroviruses and human cardiac myosin. Proc Natl Acad Sci USA. 1992;89:1320-4.
113. Dybwad A, Forre O, Siuod M. Increased serum and synovial antibodies to immunoselected peptides in patients with rheumatoid arthritis. Ann Rheum Dis. 1996;55:437-41.
114. Fielder M, Pirt SJ, Tarpey I, Wilson C, Cunningham P, Ettelaie C, et al. Molecular mimicry and ankylosing spondylitis: possible role of a novel sequence in pullulanase of Klebsiella pneumoniae. FEBS Lett. 1995;369:243-8.
115. Mobley LTH, Chippendale GR, Swihart KG, Welch RA. Cytotoxicity of the Hpm A haemolysin and urease of Proteus mirabilis, Proteus vulgarisagainst cultured renal proximal tubular epithelial cells. Infect Immun. 1991;59:2036-42.
116. Morgan K, Clague RB, Collins I, Ayad S, Phinn SD, Holt PJL. Incidence of antibodies to native and denatured cartilage collagens (types II, IX and XI) and type I collagen in rheumatoid arthritis. Ann Rheum Dis. 1987;46:902-7.
117. Musher DM, Griffith DP, Yawn D, Rossen RD. The role of urease in pyelonephritis resulting in urinary tract infection with Proteus. J Infect Dis. 1975;31:177-81.
118. Newkirk MM, Goldbach-Mansky R, Senior BW, Klippel J, Schumacher HR, El-Gabalawy HS. Elevated levels of IgA and IgM antibodies to Proteus mirabilisand IgM antibodies to Escherichia coliare associated with early rheumatoid factor (RF) positive rheumatoid arthritis. Rheumatology (Oxford). 2005;44:1433-41.
119. Peerbooms PGH, Marian A, Verweij JJ, MacLaren DM. Vero cell invasiveness of Proteus mirabilis. Infect Immun. 1984;43:1068-71.
120. Senior BW, McBride RDP, Morley KD, Kerr MA. The detection of raised levels of IgM to Proteus mirabilisin sera from patients with rheumatoid arthritis. J Med Microbiol. 1995;43:176-84.
121. Takeuchi F, Kosuge E, Matsuta K, Nakano K, Tokunaga K, Juji T et al. Antibody to a specific HLA-B1 sequence in Japanese patients with rheumatoid arthritis. Arthritis Rheum. 1990;33: 1867-8.
122. Wilson C, Rashid T, Tiwana H, Beyan H, Hughes L, Bansal S, et al. Cytotoxicity responses to peptide antigens in rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 2003;30:972-8.
123. Popper Karl R. The logic of scientific discovery. London: Hutchinson of London; 1959.
124. Popper Karl R. Conjectures and refutations. The growth of scientific knowledge. London: London Routledge and Kegan Paul; 1963.
125. Popper Karl R. Objective knowledge. An evolutionary approach. Oxford: Oxford University Press; 1972. p. 181.
126. Popper Karl R. Unended quest. An intellectual autobiography. London: Fontana; 1976.
127. Popper Karl R. Towards an evolutionary theory of knowledge. In: Karl Popper, editor. All life is problem solving. Oxon: Routledge; 1999. p. 57-73.
128. Russell B. History of western philosophy. London: George Allen & Unwin; 1946.
129. Singer C, Underwood EA. A short history of medicine. Oxford: Oxford Clarendon Press; 1962. p. 32.
130. Avakian H, Welsh J, Ebringer A, Entwistle CC. Ankylosing spondylitis, HLA-B27 and Klebsiella. II. Cross-reactivity studies with human tissue typing sera. Br J Exp Pathol. 1980;61:92-6.
131. Avorn J, Monane M, Gurwitz JH, Glynn RJ, Chodnovskiy I, Lipsitz LA. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA. 1994;271:751-4.
132. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: A systematic, literature review. Ann Rheum Dis. 2006;65:845-51.
133. Blankenberg-Sprenkels SHD, Fielder M, Feldkamp TEW, Tiwana H, Wilson C, Ebringer A. Antibodies to Klebsiella pneumoniae in Dutch patients with ankylosing spondylitis and acute anterior uveitis and to Proteus mirabilis in rheumatoid arthritis. J Rheumatol. 1998;25:743-7.
134. Deighton CM, Gray SW, Biant AJ, Walker DJ. Specificity of the Proteus antibody response in rheumatoid arthritis. Ann Rheum Dis. 1992;51:1206-7.
135. Ebringer A, Ptaszynska T, Corbett M, Wilson C, Macafee Y, Avakian H, et al. Antibodies to Proteus in rheumatoid arthritis. Lancet. 1985;2:305-7.
136. Ebringer A, Cox NL, Abuljadayel I, Ghuloom M, Khalafpour S, Ptaszynska T, et al. Klebsiella antibodies in ankylosing spondylitis and Proteus antibodies in rheumatoid arthritis. Br J Rheumatol. 1988;27(Suppl II):72-85.
137. Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis: proposal for the early use of anti-bacterial therapy. Scand J Rheumatol. 2003;32:2-11.
138. Ebringer A, Rashid T, Wilson C. Rheumatoid arthritis, Proteus, anti- CCP antibodies and Karl Popper. Autoimmun Rev. 2010;9:216-23.
139. Fielder M, Tiwana H, Youinou P, Le Goff P, Deonarian R, Wilson C, et al. The specificity of the anti-Proteus antibody response in tissue- Typed rheumatoid arthritis (RA) patients from Brest. Rheumatol Int. 1995;15:79-82.
140. Khalafpour S, Ebringer A, Abuljadayel I, Corbett M. Antibodies to Klebsiella and Proteus microrganisms in ankylosing spondylitis and rheumatoid arthritis patients measured by ELISA. Br J Rheumatol. 1988;27(Suppl II):86-9.
141. Newkirk MM, Goldbach-Mansky R, Senior BW, Klippel J, Schumacher Jr HR, El-Gabalawy HS. Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)-positive rheumatoid arthritis. Rheumatology. 2005;44: 1433-41.
142. Nymand G. Maternal smoking and immunity. Lancet. 1974;2: 1379-80.
143. O'Dell JR, Paulsen G, Haire CE, Blakely K, Palmer W, Wees S, et al. Treatment of early seropositive rheumatoid arthritis with minocycline. Arthritis Rheum. 1999;42:1691-5.
144. Rashid T, Ebringer A. Rheumatoid arthritis is linked to Proteus - The evidence. Clin Rheumatol. 2007a;26:1036-43.
145. Rashid T, Jayakumar KS, Binder A, Ellis S, Cunningham P, Ebringer A. Rheumatoid arthritis patients have elevated antibodies to cross-reactive and non-cross reactive antigens from Proteus microbes. Clin Exp Rheumatol. 2007b;25:259-67.
146. Rashid T, Leirisalo-Repo M, Tani Y, Hukuda S, Kobayashi S, Wilson C, et al. Antibacterial and antipeptide antibodies in Japanese and Finnish patients with rheumatoid arthritis. Clin Rheumatol. 2004;23:134-41.
147. Schellekens GA, de Jong BA, Van den Hoogen FH, Van de Putte LB, van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis specific auto-antibodies. J Clin Invest. 1998;101:273-81.
148. Subair H, Tiwana H, Fielder M, Binder A, Cunningham K, Ebringer A, et al. Elevation in anti-Proteus antibodies in patients with rheumatoid arthritis from Bermuda and England. J Rheumatol. 1995;22:1825-8.
149. Tani Y, Tiwana H, Hukuda S, Nishioka J, Fielder M, Wilson C, et al. Antibodies to Klebsiella, Proteus and HLA-B27 peptides in Japanese patients with ankylosing spondylitis and rheumatoid arthritis. J Rheumatol. 1997;24:109-14.
150. Tiwana H, Wilson C, Cunningham P, Binder A, Ebringer A. Antibodies to four gram-negative bacteria in rheumatoid arthritis which share sequences with the rheumatoid arthritis susceptibility motif. Br J Rheumatol. 1996;35:592-4.
151. Tiwana H, Wilson C, Walmsley RS, Wakefield AJ, Smith MSN, Cox NL, et al. Antibody responses to gut bacteria in ankylosing spondylitis, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Rheumatol Int. 1997;17:11-6.
152. Vital EM, Emery P. The development of targeted therapies in rheumatoid arthritis. J Autoimmun. 2008;31:219-27.
153. Wanchu A, Deodhar SD, Sharma M, Gupta V, Bambery P, Sud A. Elevated levels of anti-Proteus antibodies in patients with active rheumatoid arthritis. Indian J Med Res. 1997;105:39-42.
154. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy. Arthritis Rheum. 2007;56:2886-95.
155. Zintzaras E, Dahabreh LJ, Giannouli S, Voulgarelis M, Moutsopoulos HM. Infliximab and methotrexate in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of dosage regimens. Clin Ther. 2008;30:1939-55.